Sanofi (NASDAQ:SNY) Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC reduced its holdings in Sanofi (NASDAQ:SNY - Free Report) by 8.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 246,711 shares of the company's stock after selling 23,129 shares during the period. Clearbridge Investments LLC's holdings in Sanofi were worth $11,899,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in SNY. Synergy Asset Management LLC purchased a new stake in Sanofi during the 4th quarter valued at $25,000. McClarren Financial Advisors Inc. increased its position in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new stake in shares of Sanofi in the fourth quarter valued at $31,000. Sunbelt Securities Inc. raised its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after acquiring an additional 313 shares during the period. Finally, Sierra Ocean LLC bought a new stake in shares of Sanofi in the 4th quarter worth about $44,000. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SNY shares. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Remove Ads

Sanofi Stock Down 4.8 %

Sanofi stock traded down $2.64 during midday trading on Friday, hitting $51.98. 3,162,438 shares of the company's stock were exchanged, compared to its average volume of 2,285,156. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12. The firm has a 50-day moving average of $55.37 and a two-hundred day moving average of $52.71. The company has a market cap of $131.92 billion, a PE ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.